

CLINICAL CASE CONFERENCE

Provided by Rutgers New Jersey Medical School, Department of Medicine

"25-year-old man presenting with rectal pain and hematochezia" Thursday, June 27, 2024, 12:00-1:00 pm

Yasmeen Abdo, MD – Resident Rutgers New Jersey Medical School

Objectives:

At the conclusion of this activity, participants should be better able to:

- 1. Describe the state-of-the-art evaluation and management of patients with specific disease states
- 2. Implement clinical practice guidelines and best practices to provide optimal therapy for patients
- 3. Recognize the impact of physical, social and economic factors on patient health within the community

Target Audience: This activity is designed for physicians, physician assistants, nurse practitioners, fellows, residents, medical students, nurses and other medical personnel in the subspecialties of Internal Medicine.



Accreditation: In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Declarations: Dr. Yasmeen Abdo has no relevant financial relationships with ineligible companies to disclose. The discussant will disclose his/her financial relationships with ineligible companies, if any at the time of the activity. Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Content Reviewers: Drs. Daniel Matassa and Jared Walsh, and Drs. Saahil A. Jumkhawala and Brooke E. Baker have no relevant financial relationships with ineligible companies to disclose.

RBHS CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.